Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Weight loss can make parts of your body look different
Retatrutide is an unlicensed investigational peptide in the UK with no MHRA or EMA marketing authorisation as of 2024
Exenatide, the active ingredient in Bydureon BCise, was the first GLP-1 medication to be approved by the FDA
Readers should verify the current authorisation status via the MHRA and EMA medicines databases, as the regulatory position may change as Phase 3 data mature
So your prescriber will work with you to find the closest equivalent
New indications expand use cases Perhaps just as important as the wave of new GLP-1/GIP drugs for obesity is the expansion of already approved GLP-1 drugs into other therapeutic areas
US$ 22.42
US$ 22.49
US$ 26.10
